Skip to main content

Table 4 Distribution of antimicrobial resistance in Haemophilus influenzae and Haemophilus parainfluenzae isolates in healthy people and in patients with sarcoidosis

From: Changes in the prevalence and biofilm formation of Haemophilus influenzae and Haemophilus parainfluenzae from the respiratory microbiota of patients with sarcoidosis

  

No. (%) of resistant isolates

Species

Place of isolation

Sxt

Te

Ctx

Caz

Sam

AmC

Am

Healthy people

Haemophilus influenzae (n = 1)

Nasopharynx (n = 1)

0

0

0

0

0

0

0

Haemophilus parainfluenzae (n = 65)

Nasopharynx (n = 65)

8 (12.3)

4 (6.2)

4 (6.2)

5 (7.7)

3 (4.6)

1 (1.5)

10 (15.4)

Patients with sarcoidosis

Haemophilus influenzae (n = 19)

Nasopharynx (n = 6)

1 (16.7)

0

0

0

0

1 (16.7)

0

Sputum (n = 13)

1 (7.7)

2 (15.4)

0

0

0

0

0

Haemophilus parainfluenzae (n = 96)

Nasopharynx (n = 47)

10 (21.3)

9 (19.1)

2 (4.3)

3 (6.4)

0

0

6 (12.8)

Sputum (n = 49)

8 (16.3)

6 (12.2)

1 (2.0)

5 (10.2)

0

0

2 (4.1)

  1. Abbreviations: Am ampicillin, AmC amoxycillin/clavulanate, Caz ceftazidime, Ctx cefotaxime, Sam ampicillin-sulbactam, Sxt trimethoprim/sulfametoxazole, Te tetracycline